Interestingly, the transcription level of SFT2D2‐TBX19 was highest in the neuroendocrine prostate cancer (NEPC) cell line NCI‐H660 (Figure S1E, Supporting Information), suggesting that SFT2D2‐TBX19 may be correlated with the malignant progression of prostate cancer. Here, SFT2D2 is linked to prostate carcinoma.